СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ АНТАГОНИСТОВ CRTH2 РЕЦЕПТОРОВ

摘要

Compounds of general formula (I): wherein R¹, R², R³ and R⁴ are independently hydrogen, halo, C₁-C₆ alkyl, -O(C₁-C₆ alkyl), -CON(R⁹)₂, -SOR⁹, -SO₂R⁹, -SO₂N(R⁹)₂, -N(R⁹)₂, -NR⁹COR⁹, -CO₂R⁹, -COR⁹, -SR⁹, -OH, -NO₂ or -CN; each R⁹ is independently hydrogen or C₁-C₆ alkyl; R⁵ and R⁶ are each independently hydrogen, or C₁-C₆ alkyl or together with the carbon atom to which they are attached form a C₃-C₇ cycloalkyl group; R⁷ is hydrogen or C₁-C₆ alkyl n is 1 or 2; X is a bond or, when n is 2, X may also be a NR⁹ group; wherein R⁹ is as defined above; when X is a bond R⁸ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, biphenyl or a 9-14 membered bicyclic or tricyclic heteroaryl group; when X is a NR⁹ group R⁸ may additionally be phenyl, naphthyl or a 5-7 membered heteroaromatic ring; and the R⁸ group is optionally substituted with one or more substituents selected from halo, C₁-C₆ alkyl, -O(C₁-C₆)alkyl, aryl, -O-aryl, heteroaryl, -O-heteroaryl, -CON(R⁹)₂, -SOR⁹, -SO₂R⁹, SO₂N(⁹)₂, -N(⁹)₂, -NR⁹COR⁹, -CO₂R⁹, -COR⁹, -SR⁹, -OH, -NO₂ or -CN; wherein R⁹ is as defined above; and their pharmaceutically acceptable salts, hydrates, solvates, complexes and prodrugs are useful in the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.